Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
0 hedge funds and large institutions have $0 invested in Verve Therapeutics in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $344K → $0 (-$344K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$344K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$344K | -24,000 | Closed |
|
VERV Hedge Fund Activity: Q1 2026 in Review
0 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q1 2026, worth a combined $0 — down 100% from $344K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VERV and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $344K sold.
- 0 institutional investors held Verve Therapeutics (VERV) as of Q1 2026, down from 1 in Q4 2025.
- Funds reported $0 of Verve Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Verve Therapeutics positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Verve Therapeutics seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $344K sold.
Based on aggregated 13F filings for Q1 2026.